GlassScriptPhysician profile
Joan Cerra
NPI 1710153101
$1,088.27
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,088.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $146.43 | 2021 | |
| Glaxosmithkline, LLC. | $142.34 | 2021 | |
| Abbvie INC. | $141.85 | 2021 | |
| Astellas Pharma US INC | $77.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $71.95 | 2021 | |
| Pfizer INC. | $66.92 | 2021 | |
| Esperion Therapeutics, INC. | $58.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $56.59 | 2021 | |
| Biogen, INC. | $47.05 | 2021 | |
| Dexcom, INC. | $33.26 | 2021 | |
| Kaleo, INC. | $31.88 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.83 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $30.10 | 2021 | |
| Lilly USA, LLC | $29.17 | 2021 | |
| Amarin Pharma, INC. | $27.19 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $26.60 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.87 | 2021 | |
| Radius Health, INC. | $14.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2021 | |
| Daiichi Sankyo INC. | $11.82 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Cerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.